Related Experiment Videos
Cardiopulmonary bypass (CPB) for lung transplantation
C C Hlozek1, N G Smedira, T J Kirby
1Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Foundation, Ohio, USA.
Perfusion
|March 1, 1997
Summary
Cardiopulmonary bypass (CPB) is safe and effective for lung transplant recipients, even those with severe conditions. Concerns about adverse effects are not supported by this study, suggesting CPB should not be avoided.
Area of Science:
- Cardiology
- Thoracic Surgery
- Transplantation Medicine
Background:
- Cardiopulmonary bypass (CPB) use in lung transplantation is debated due to potential complications.
- Adverse sequelae include hemorrhage, complement activation, and endothelial damage.
Purpose of the Study:
- To evaluate the safety and efficacy of CPB in lung transplant recipients.
- To clarify the impact of CPB on outcomes in single (SLTx) and double lung (DLTx) transplantation.
Main Methods:
- Retrospective review of 74 lung transplant patients over four years.
- 30 patients required CPB support for indications like pulmonary hypertension and hemodynamic instability.
- CPB cannulation strategies varied for SLTx (femoral) and DLTx (aorta/atrium).
Main Results:
- Hemorrhage was not a significant issue during or after CPB.
- 30-day mortality was 20% for the CPB group and 4.6% for the non-CPB group (p=0.06).
- No statistically significant difference in 30-day mortality between groups.
Conclusions:
- CPB is a safe and effective method for supporting severely ill lung transplant patients.
- Concerns regarding CPB-related adverse sequelae should not preclude its use.
- CPB can improve postoperative graft function and patient outcomes.